The ongoing phase I/II study with 40 patients is due to complete in May/June 2019. The last study patient is expected to undergo scheduled surgery…
Read More
The phase I/II study in patients with bladder cancer addresses the safety of our drug candidate Alpha1H and measures biomarkers of efficacy. The protocol is…
HAMLET Pharma AB is pleased to announce that we have received a notification from the European Patent Office (EPO) regarding a patent application with claims…
Hamlet Pharma takes a further step towards the start of the clinical study in patients with bladder cancer. The company has received ethical approval of…
Hamlet Pharma announces that the production of the Alpha1H peptide has been successful and that the peptide is ready for delivery. The peptide meets the…
On April 11th, the British newspaper The Daily Telegraph published a feature article about HAMLET and the founder of Hamlet Pharma Professor Catharina Svanborg, following…